IMMUNE PROFILING TO INVESTIGATE IMPROVED SURVIVAL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RECEIVING TRILACICLIB PRIOR TO CHEMOTHERAPY

被引:1
|
作者
Stevens, Aaron [1 ]
O'Shaughnessy, Joyce [2 ]
Cao, Subing [1 ]
Sorrentino, Jessica [1 ]
Horton, Janet [1 ]
Yi, John [1 ]
Tan, Antoinette [3 ]
机构
[1] G1 Therapeutics Inc, Res Triangle Pk, NC USA
[2] Baylor Univ, Med Ctr, Texas Oncol Dallas, US Oncol Res, Dallas, TX USA
[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
关键词
D O I
10.1136/jitc-2021-SITC2021.339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
339
引用
收藏
页码:A365 / A365
页数:1
相关论文
共 50 条
  • [31] Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival
    Sinn, H.
    Elsawaf, Z.
    Bermejo, J. L.
    Aulmann, S.
    Rom, J.
    Schneeweiss, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Predictors of Survival in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiotherapy
    Shao, S.
    Shi, W.
    Zhang, L.
    Meng, J.
    Guo, X. M.
    Yu, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E333 - E333
  • [33] Trilaciclib induces immune changes within the tumor microenvironment in early-stage triple-negative breast cancer
    Danso, Michael
    O'Shaughnessy, Joyce
    Wang, Lisa S.
    Mosalpuria, Kailash
    Hurvitz, Sara
    Goel, Shom
    Ahn, Sarah
    Cao, Subing
    Yi, John S.
    Oyekunle, Taofik
    Jacobson, Amanda
    Beelen, Andrew
    Force, Jeremy
    CANCER RESEARCH, 2023, 83 (05)
  • [34] Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
    Gerashchenko, T. S.
    Frolova, A.
    Fedorov, A. A.
    Patysheva, M.
    Vashisth, M.
    Iamshchikov, P.
    Bragina, O.
    Cherdyntseva, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S214 - S214
  • [35] Predicting response and survival in chemotherapy-treated triple-negative breast cancer
    A Prat
    A Lluch
    J Albanell
    W T Barry
    C Fan
    J I Chacón
    J S Parker
    L Calvo
    A Plazaola
    A Arcusa
    M A Seguí-Palmer
    O Burgues
    N Ribelles
    A Rodriguez-Lescure
    A Guerrero
    M Ruiz-Borrego
    B Munarriz
    J A López
    B Adamo
    M C U Cheang
    Y Li
    Z Hu
    M L Gulley
    M J Vidal
    B N Pitcher
    M C Liu
    M L Citron
    M J Ellis
    E Mardis
    T Vickery
    C A Hudis
    E P Winer
    L A Carey
    R Caballero
    E Carrasco
    M Martín
    C M Perou
    E Alba
    British Journal of Cancer, 2014, 111 : 1532 - 1541
  • [36] Predicting response and survival in chemotherapy-treated triple-negative breast cancer
    Prat, A.
    Lluch, A.
    Albanell, J.
    Barry, W. T.
    Fan, C.
    Chacon, J. I.
    Parker, J. S.
    Calvo, L.
    Plazaola, A.
    Arcusa, A.
    Segui-Palmer, M. A.
    Burgues, O.
    Ribelles, N.
    Rodriguez-Lescure, A.
    Guerrero, A.
    Ruiz-Borrego, M.
    Munarriz, B.
    Lopez, J. A.
    Adamo, B.
    Cheang, M. C. U.
    Li, Y.
    Hu, Z.
    Gulley, M. L.
    Vidal, M. J.
    Pitcher, B. N.
    Liu, M. C.
    Citron, M. L.
    Ellis, M. J.
    Mardis, E.
    Vickery, T.
    Hudis, C. A.
    Winer, E. P.
    Carey, L. A.
    Caballero, R.
    Carrasco, E.
    Martin, M.
    Perou, C. M.
    Alba, E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (08) : 1532 - 1541
  • [37] Improved outcome of metastatic triple negative breast cancer patients treated with cisplatin based chemotherapy
    Koshy, Nebu
    Quispe, Dolly
    Shi, Runhua
    Mansour, Richard
    Burton, Gary
    CANCER RESEARCH, 2009, 69
  • [38] Effect of neoadjuvant chemotherapy on disease free survival and over all survival in triple-negative breast cancer patients
    Gill, J.
    Mishra, A. N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
    Anders, Carey K.
    Carey, Lisa A.
    CLINICAL BREAST CANCER, 2009, 9 : S73 - S81